Company: BIAF
Filing Date: 2025-05-15
Form Type: 10-Q
Source: 0001641172-25-010787
Chunk: 39

Company: bioAffinity Technologies, Inc.
Filing Date: 2025-05-15
Form: 10-Q
Item: Part I, Item 8
Chunk 39
---
reciation and amortization 
     154,588  
     149,637 

    Total operating expenses 
     4,480,736  
     4,351,621 

    Loss from operations 
     (2,627,139) 
     (1,945,230)

    Other income (expense): 

    Interest income 
     542  
     6,127 
  
    Interest expense 
     (15,485) 
     (23,550)
  
    Other income 
     2  
     4,510 
  
    Other expense 
     (9,642) 
     — 

    Total other expense 
     (24,583) 
     (12,913)

    Net loss before provision for income taxes 
     (2,651,722) 
     (1,958,143)

    Income tax expense 
     (8,695) 
     (3,672)

    Net loss 
    $(2,660,417) 
    $(1,961,815)

    Net loss per common share, basic and diluted 
    $(0.16) 
    $(0.20)

    Weighted average common shares outstanding, basic and diluted 
     16,257,456  
     9,915,426 

The accompanying notes are an integral part of these
unaudited consolidated financial statements.

6

bioAffinity Technologies, Inc.

Unaudited Consolidated Statements of Changes in
Stockholders’ Equity

    Shares  
    Amount  
    Shares  
    Amount  
    Capital  
    Deficit  
    Equity 

    For the Three Months Ended March 31, 2025 

    Preferred Stock  
    Common Stock  
    Additional  Paid-in  
    Accumulated  
    Stockholders’ 

    Shares  
    Amount  
    Shares  
    Amount  
    Capital  
    Deficit  
    Equity 

    Balance at December 31, 2024 
     —  
    $—  
     15,227,619  
    $106,593  
    $56,139,753  
    $(53,644,310) 
    $2,602,036 

    Stock-based compensation expense 
     —  
     —  
     159